Compare Stocks: RNAZ, NXTC, JSPR, and APLT

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APLT Applied Therapeutics	$0.10	$0.10	$0.09 ▼ $1.50	$15.86M	2.08	7.28 million shs	N/A
JSPR Jasper Therapeutics	$0.79 +10.9%	$0.56	$0.32 ▼ $3.14	$22.23M	3.02	918,240 shs	486,185 shs
NXTC NextCure	$6.64 +13.7%	$3.35	$1.55 ▼ $15.74	$24.04M	1.26	917,179 shs	1.17 million shs
RNAZ TransCode Therapeutics	$4.05 +2.3%	$6.19	$3.82 ▼ $20.99	$4.37M	1.24	129,705 shs	15,693 shs

7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APLT Applied Therapeutics	0.00%	0.00%	0.00%	0.00%	-75.80%
JSPR Jasper Therapeutics	0.00%	+12.62%	+22.43%	-24.70%	-71.04%
NXTC NextCure	0.00%	+41.06%	+196.45%	-40.29%	+19.92%
RNAZ TransCode Therapeutics	0.00%	-13.16%	-55.15%	-43.43%	-61.89%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APLT Applied Therapeutics	$0.10	$0.10	$0.09 ▼ $1.50	$15.86M	2.08	7.28 million shs	N/A
JSPR Jasper Therapeutics	$0.79 +10.9%	$0.56	$0.32 ▼ $3.14	$22.23M	3.02	918,240 shs	486,185 shs
NXTC NextCure	$6.64 +13.7%	$3.35	$1.55 ▼ $15.74	$24.04M	1.26	917,179 shs	1.17 million shs
RNAZ TransCode Therapeutics	$4.05 +2.3%	$6.19	$3.82 ▼ $20.99	$4.37M	1.24	129,705 shs	15,693 shs

7 Stocks That Could Lead the Next Market Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APLT Applied Therapeutics	0.00%	0.00%	0.00%	0.00%	-75.80%
JSPR Jasper Therapeutics	0.00%	+12.62%	+22.43%	-24.70%	-71.04%
NXTC NextCure	0.00%	+41.06%	+196.45%	-40.29%	+19.92%
RNAZ TransCode Therapeutics	0.00%	-13.16%	-55.15%	-43.43%	-61.89%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APLT Applied Therapeutics	1.67	Reduce	$1.00	870.87% Upside
JSPR Jasper Therapeutics	2.38	Hold	$12.00	1,424.78% Upside
NXTC NextCure	2.25	Hold	$19.00	186.14% Upside
RNAZ TransCode Therapeutics	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest RNAZ, NXTC, JSPR, and APLT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/17/2026	JSPR Jasper Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/17/2026	RNAZ TransCode Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/15/2026	NXTC NextCure	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$20.00
7/7/2026	NXTC NextCure	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/11/2026	NXTC NextCure	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
5/15/2026	JSPR Jasper Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target	Sector Perform	$4.00 ➝ $3.00
5/15/2026	JSPR Jasper Therapeutics	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Hold

(Data available from 8/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APLT Applied Therapeutics	$1M	15.86	N/A	N/A	$0.49 per share	0.21
JSPR Jasper Therapeutics	N/A	N/A	N/A	N/A	$0.15 per share	N/A
NXTC NextCure	N/A	N/A	N/A	N/A	$9.97 per share	N/A
RNAZ TransCode Therapeutics	N/A	N/A	N/A	N/A	$11.27 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APLT Applied Therapeutics	-$105.62M	-$0.10	N/A	N/A	N/A	N/A	-340.84%	-175.00%	N/A
JSPR Jasper Therapeutics	-$75.80M	-$3.23	N/A	N/A	N/A	N/A	-613.51%	-162.52%	8/12/2026 (Estimated)
NXTC NextCure	-$55.84M	-$8.70	N/A	N/A	N/A	N/A	-154.62%	-100.19%	N/A
RNAZ TransCode Therapeutics	-$34.66M	-$50.33	N/A	N/A	N/A	N/A	-875.35%	-50.36%	8/18/2026 (Estimated)

Latest RNAZ, NXTC, JSPR, and APLT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	JSPR Jasper Therapeutics	-$0.2471	N/A	N/A	N/A	N/A	N/A
8/6/2026	Q2 2026	NXTC NextCure	-$1.95	-$2.80	-$0.85	-$2.80	N/A	N/A
5/15/2026	Q1 2026	RNAZ TransCode Therapeutics	N/A	-$21.28	N/A	-$21.28	N/A	N/A
5/14/2026	Q1 2026	JSPR Jasper Therapeutics	-$0.46	-$0.38	+$0.08	-$0.04	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
APLT Applied Therapeutics	N/A	N/A	N/A	N/A	N/A
JSPR Jasper Therapeutics	N/A	N/A	N/A	N/A	N/A
NXTC NextCure	N/A	N/A	N/A	N/A	N/A
RNAZ TransCode Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APLT Applied Therapeutics	N/A	0.96	0.96
JSPR Jasper Therapeutics	N/A	2.26	2.26
NXTC NextCure	N/A	3.47	3.47
RNAZ TransCode Therapeutics	N/A	3.11	3.11

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
APLT Applied Therapeutics	98.31%
JSPR Jasper Therapeutics	79.85%
NXTC NextCure	42.65%
RNAZ TransCode Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
APLT Applied Therapeutics	1.60%
JSPR Jasper Therapeutics	2.30%
NXTC NextCure	11.90%
RNAZ TransCode Therapeutics	0.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
APLT Applied Therapeutics	30	153.96 million	151.50 million	Optionable
JSPR Jasper Therapeutics	20	28.00 million	27.35 million	Optionable
NXTC NextCure	90	3.61 million	3.18 million	No Data
RNAZ TransCode Therapeutics	9	1.06 million	1.06 million	Not Optionable

RNAZ, NXTC, JSPR, and APLT Headlines

Recent News About These Companies

Virax Biolabs and Transcode Therapeutics Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TV

August 7 at 9:19 AM | finance.yahoo.com

TransCode Therapeutics, Inc.

July 22, 2026 | edition.cnn.com

TransCode Therapeutics Inc RNAZ

July 3, 2026 | morningstar.comM

TransCode Therapeutics, Inc. (RNAZ) Discusses Strategic, Scientific, and Clinical Updates With Focus on TTX-MC138 Phase 2a Trial in Colorectal Cancer Prepared Remarks Transcript

June 18, 2026 | seekingalpha.com

RNAZ: Introducing RNA therapeutics

June 8, 2026 | msn.com

TransCode Therapeutics to Host R&D Webcast on June 18, 2026

June 8, 2026 | prnewswire.com

RNAZ Share News Today

June 4, 2026 | uk.investing.com

EXCLUSIVE: TransCode's RNA Therapeutic Achieves 64% Stable Disease Rate In Colorectal Cancer Phase 1 Study

June 3, 2026 | finance.yahoo.com

TransCode Therapeutics Successfully Completes Phase 1a Clinical Trial, Reports Safety and Stabilization Data for TTX-MC138 in Metastatic Cancer

June 3, 2026 | prnewswire.com

TransCode Therapeutics, Inc.: TransCode Therapeutics Initiates Phase 2a Clinical Trial with TTX-MC138 in Patients with ctDNA Positive Colorectal Cancer

May 28, 2026 | finanznachrichten.de

TransCode Therapeutics Initiates Phase 2a Clinical Trial with TTX-MC138 in Patients with ctDNA Positive Colorectal Cancer

May 27, 2026 | prnewswire.com

TransCode Therapeutics Appoints Dr. Anna Moore as Chair of Scientific Advisory Board; Announces Sponsored Research Agreement with Michigan State University

April 27, 2026 | prnewswire.com

TransCode Therapeutics signs financing deal worth up to $20 million

April 8, 2026 | msn.com

TransCode Therapeutics Enters into Agreements for up to $20 Million Flexible Financing, Extending Company's Runway into Late 2027/Early 2028

April 7, 2026 | prnewswire.com

TransCode Secures Exclusive, Worldwide, Fully Paid-Up Royalty-Free License to Develop and Commercialize a Next-Generation Oncolytic Immunotherapy Platform in an All-Stock Transaction Underscoring the Company's Dedication to Improving the Lives of Cancer Patients

March 3, 2026 | prnewswire.com

TransCode Therapeutics Announces Publication of Preclinical Testing of RIG-I Immunotherapeutic Candidate Supporting Further Development

February 23, 2026 | prnewswire.com

TransCode Therapeutics Advances Phase 2a Colorectal Cancer Trial

February 11, 2026 | theglobeandmail.com

TransCode Therapeutics, Inc.: TransCode Therapeutics and Quantum Leap Announce Submission of IND Amendment for Phase 2a Clinical Trial with TTX-MC138

February 5, 2026 | finanznachrichten.de

TransCode Therapeutics and Quantum Leap Announce Submission of IND Amendment for Phase 2a Clinical Trial with TTX-MC138

February 5, 2026 | prnewswire.com

TransCode Therapeutics reports promising preclinical glioblastoma results

January 6, 2026 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

RNAZ, NXTC, JSPR, and APLT Company Descriptions

Applied Therapeutics NASDAQ:APLT

$0.10 0.00 (0.00%)

As of 08/7/2026

Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG. It also develops AT-001 (also called caficrestat) that is in phase 3 clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy. The company has exclusive license and supply agreement with Mercury Pharma Group Limited to commercialize drug products containing AT-007. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.

Jasper Therapeutics NASDAQ:JSPR

$0.79 +0.08 (+10.92%)

As of 02:48 PM Eastern

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and conditioning regimens for stem cell transplantation. In addition, it is also developing stem cell transplants for rare diseases such as sickle cell disease, fanconi anemia, chronic granulomatous diseases, and GATA2 MDS, and severe combined immunodeficiency. Jasper Therapeutics, Inc. is headquartered in Redwood City, California.

NextCure NASDAQ:NXTC

$6.64 +0.80 (+13.70%)

As of 02:47 PM Eastern

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. It has a license agreement with Yale University. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland.

TransCode Therapeutics NASDAQ:RNAZ

$4.05 +0.09 (+2.30%)

As of 02:46 PM Eastern

TransCode Therapeutics, Inc., a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. The company is also developing TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; and TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. In addition, the company developing TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines that activate cytotoxic immune responses against tumor cells. TransCode Therapeutics, Inc. was incorporated in 2016 and is based in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RNAZ, NXTC, JSPR, and APLT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RNAZ, NXTC, JSPR, and APLT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RNAZ, NXTC, JSPR, and APLT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

RNAZ, NXTC, JSPR, and APLT Company Descriptions

Applied Therapeutics NASDAQ:APLT

Jasper Therapeutics NASDAQ:JSPR

NextCure NASDAQ:NXTC

TransCode Therapeutics NASDAQ:RNAZ

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RNAZ, NXTC, JSPR, and APLT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RNAZ, NXTC, JSPR, and APLT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RNAZ, NXTC, JSPR, and APLT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

RNAZ, NXTC, JSPR, and APLT Company Descriptions

Applied Therapeutics NASDAQ:APLT

Jasper Therapeutics NASDAQ:JSPR

NextCure NASDAQ:NXTC

TransCode Therapeutics NASDAQ:RNAZ

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools